# Phase 1/2a for Safety, PK and PD of SQY51 in Paediatric and Adult Patients Duchenne Muscular Dystrophy

> **NCT05753462** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sqy Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Phase 1, SQY51
- **DRUG:** Phase 2a, SQY51 (cohort 1)
- **DRUG:** Phase 2a, SQY51 (cohort 2)
- **DRUG:** Phase 2a, SQY51 (cohort 3)

## Key facts

- **NCT ID:** NCT05753462
- **Lead sponsor:** Sqy Therapeutics
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-26
- **Primary completion:** 2025-02
- **Final completion:** 2025-02
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05753462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05753462, "Phase 1/2a for Safety, PK and PD of SQY51 in Paediatric and Adult Patients Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05753462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*